Literature DB >> 21115887

Real-time imaging of tumor progression in a fluorescent orthotopic mouse model of thyroid cancer.

Hop S Tran Cao1, Sharmeela Kaushal, Cynthia S Snyder, Weg M Ongkeko, Robert M Hoffman, Michael Bouvet.   

Abstract

There is a need for a clinically relevant mouse model of thyroid cancer that enables real-time, non-invasive monitoring of tumor growth, progression, and drug response over time. Human thyroid cancer cell lines NPA (papillary) and KAK-1 (anaplastic) were stably transfected to express either red or green fluorescent protein. Cancer cells were injected into the thyroid glands of 8-week-old athymic mice. The animals were imaged with whole-body fluorescence imaging weekly and sacrificed when premorbid. At necropsy, the primary tumor was resected en bloc with the respiratory system for processing and analysis. Histology was performed on fixed tissue specimens for review of morphologic findings. Both anaplastic and papillary thyroid cancer cell lines led to robust development of orthotopic fluorescent tumors in nude mice. Injection of 5×10(5) cancer cells was sufficient for tumor development. Tumors were visualized for both cell lines via non-invasive imaging as early as 3 weeks post-implantation and were monitored over time. Time to premorbid condition varied between mice and was associated with a primary tumor growth pattern (early local compression of the esophagus vs. late metastatic disease) rather than tumor size. At necropsy, tumor fluorescence demonstrated metastases in the lungs, lymph nodes and vessels that were not visible under white light. Thus an orthotopic mouse model of thyroid cancer has been developed that replicates the major clinical features of thyroid cancer and enables real-time, non-invasive monitoring of tumor progression. This model should permit preclinical evaluation of novel thyroid cancer therapeutics.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21115887      PMCID: PMC4453926     

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  35 in total

1.  Whole-body optical imaging of green fluorescent protein-expressing tumors and metastases.

Authors:  M Yang; E Baranov; P Jiang; F X Sun; X M Li; L Li; S Hasegawa; M Bouvet; M Al-Tuwaijri; T Chishima; H Shimada; A R Moossa; S Penman; R M Hoffman
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

2.  The tyrosine kinase inhibitor, AZD2171, inhibits vascular endothelial growth factor receptor signaling and growth of anaplastic thyroid cancer in an orthotopic nude mouse model.

Authors:  Fernando Gomez-Rivera; Alfredo A Santillan-Gomez; Maher N Younes; Seungwon Kim; David Fooshee; Mei Zhao; Samar A Jasser; Jeffrey N Myers
Journal:  Clin Cancer Res       Date:  2007-08-01       Impact factor: 12.531

3.  Tyrosine kinase inhibitor STI571 enhances thyroid cancer cell motile response to Hepatocyte Growth Factor.

Authors:  F Frasca; P Vigneri; V Vella; R Vigneri; J Y Wang
Journal:  Oncogene       Date:  2001-06-28       Impact factor: 9.867

4.  Subcellular imaging in the live mouse.

Authors:  Robert M Hoffman; Meng Yang
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

5.  High correlation of whole-body red fluorescent protein imaging and magnetic resonance imaging on an orthotopic model of pancreatic cancer.

Authors:  Michael Bouvet; Joseph Spernyak; Matthew H Katz; Richard V Mazurchuk; Shinako Takimoto; Ralph Bernacki; Youcef M Rustum; Abdool R Moossa; Robert M Hoffman
Journal:  Cancer Res       Date:  2005-11-01       Impact factor: 12.701

6.  An orthotopic model of papillary thyroid carcinoma in athymic nude mice.

Authors:  Soon-Hyun Ahn; Ying Henderson; Ya'an Kang; Chandrani Chattopadhyay; Paula Holton; Mary Wang; Katrina Briggs; Gary L Clayman
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2008-02

Review 7.  Anaplastic thyroid cancer: prevalence, diagnosis and treatment.

Authors:  S Chiacchio; A Lorenzoni; G Boni; D Rubello; R Elisei; G Mariani
Journal:  Minerva Endocrinol       Date:  2008-12       Impact factor: 2.184

Review 8.  BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.

Authors:  Mingzhao Xing
Journal:  Endocr Rev       Date:  2007-10-16       Impact factor: 19.871

Review 9.  RET/PTC rearrangement in thyroid tumors.

Authors:  Yuri E Nikiforov
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

10.  Effects of tamoxifen and somatostatin analogue on growth of human medullary, follicular, and papillary thyroid carcinoma cell lines: tissue culture and nude mouse xenograft studies.

Authors:  C J Weber; M Marvin; S Krekun; T Koschitzky; F Karp; M Benson; C R Feind
Journal:  Surgery       Date:  1990-12       Impact factor: 3.982

View more
  4 in total

1.  Characterization of an Orthotopic Colorectal Cancer Mouse Model and Its Feasibility for Accurate Quantification in Positron Emission Tomography.

Authors:  Sara Rapic; Christel Vangestel; Jeroen Verhaeghe; Tim Van den Wyngaert; Rukun Hinz; Marleen Verhoye; Patrick Pauwels; Steven Staelens; Sigrid Stroobants
Journal:  Mol Imaging Biol       Date:  2017-10       Impact factor: 3.488

2.  Biological Evaluation of a Fluorescent-Imaging Agent for Medullary Thyroid Cancer in an Orthotopic Model.

Authors:  Kara K Rossfeld; Steven E Justiniano; Haiming Ding; Li Gong; Shankaran Kothandaraman; Dwitiya Sawant; Motoyasu Saji; Chadwick L Wright; Lawrence S Kirschner; Matthew D Ringel; Michael F Tweedle; John E Phay
Journal:  J Clin Endocrinol Metab       Date:  2017-09-01       Impact factor: 5.958

3.  An orthotopic mouse model of anaplastic thyroid carcinoma.

Authors:  Will Sewell; Ashley Reeb; Reigh-Yi Lin
Journal:  J Vis Exp       Date:  2013-04-17       Impact factor: 1.355

Review 4.  Preclinical Imaging for the Study of Mouse Models of Thyroid Cancer.

Authors:  Adelaide Greco; Luigi Auletta; Francesca Maria Orlandella; Paola Lucia Chiara Iervolino; Michele Klain; Giuliana Salvatore; Marcello Mancini
Journal:  Int J Mol Sci       Date:  2017-12-16       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.